comparemela.com

Latest Breaking News On - Centessa pharmaceuticals stock performance - Page 1 : comparemela.com

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven research firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month […]

Karenm-anderson
Td-asset-management-inc
Nasdaq
Centessa-pharmaceuticals
Institutional-trading-of-centessa-pharmaceuticals
Insider-activity-at-centessa-pharmaceuticals
Centessa-pharmaceuticals-stock-performance
Analyst-recommendations-for-centessa-pharmaceuticals
News-ratings-for-centessa-pharmaceuticals-daily
Acuta-capital-partners
Affinity-asset-advisors

Centessa Pharmaceuticals (NASDAQ:CNTA) Given Outperform Rating at BMO Capital Markets

BMO Capital Markets reissued their outperform rating on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Free Report) in a research report report published on Monday morning, Benzinga reports. BMO Capital Markets currently has a $15.00 price objective on the stock. Centessa Pharmaceuticals Stock Performance Shares of CNTA stock opened at $10.37 on Monday. The business has […]

China
Karenm-anderson
Harris-rotman
Susquehanna-international-group
Hedge-funds-weigh-in-on-centessa-pharmaceuticals
Analyst-recommendations-for-centessa-pharmaceuticals
Centessa-pharmaceuticals-stock-performance
Centessa-pharmaceuticals-company-profile
News-ratings-for-centessa-pharmaceuticals-daily
China-universal-asset-management-co
Barclays-plc
Centessa-pharmaceuticals

Centessa Pharmaceuticals (NASDAQ:CNTA) Trading Down 5.6%

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) fell 5.6% during mid-day trading on Monday . The stock traded as low as $11.48 and last traded at $11.52. 351,020 shares traded hands during trading, a decline of 16% from the average session volume of 419,941 shares. The stock had previously closed at $12.20. […]

Harris-rotman
Nasdaq
Goldman-sachs-group-inc
Institutional-trading-of-centessa-pharmaceuticals
News-ratings-for-centessa-pharmaceuticals-daily
Franklin-resources-inc
Securities-exchange-commission
Platinum-investment-management-ltd
Centessa-pharmaceuticals
Centessa-pharmaceuticals-stock-performance
Centessa-pharmaceuticals-company-profile
Get-free-report

Brokerages Set Centessa Pharmaceuticals plc (NASDAQ:CNTA) Price Target at $9.43

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) have earned an average rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month […]

Harris-rotman
Centessa-pharmaceuticals-stock-performance
Goldman-sachs-group
Centessa-pharmaceuticals
Morgan-stanley
Sio-capital-management
Institutional-investors-weigh-in-on-centessa-pharmaceuticals
News-ratings-for-centessa-pharmaceuticals-daily
Nasdaq
Affinity-asset-advisors
Analyst-recommendations-for-centessa-pharmaceuticals
Platinum-investment-management-ltd

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $9.17 Average Price Target from Analysts

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 […]

Harris-rotman
Analyst-recommendations-for-centessa-pharmaceuticals
Centessa-pharmaceuticals
Centessa-pharmaceuticals-company-profile
Securities-exchange-commission
News-ratings-for-centessa-pharmaceuticals-daily
Institutional-investors-weigh-in-on-centessa-pharmaceuticals
Morgan-stanley
Goldman-sachs-group
Nasdaq
Centessa-pharmaceuticals-stock-performance
Affinity-asset-advisors

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.